{"id":10100,"date":"2026-04-01T06:13:37","date_gmt":"2026-04-01T11:13:37","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10100"},"modified":"2026-04-01T06:17:26","modified_gmt":"2026-04-01T11:17:26","slug":"nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u773c\u79d1\u696d\u754c\u306e\u30d9\u30c6\u30e9\u30f3\u3067\u3042\u308b\u30dd\u30fc\u30eb\u30fb\u30cf\u30ec\u30f3\u6c0f\u3092\u6700\u9ad8\u57f7\u884c\u8cac\u4efb\u8005\uff08COO\uff09\u306b\u4efb\u547d\u3057\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u4e8b\u696d\u5c55\u958b\u6e96\u5099\u3092\u63a8\u9032"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10100\" class=\"elementor elementor-10100\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 class=\"prntac\" style=\"text-align: center;\"><em>\u7814\u7a76\u958b\u767a\u3001\u88fd\u9020\u3001\u54c1\u8cea\u7ba1\u7406\u3001\u5546\u696d\u6226\u7565\u3001\u30d5\u30e9\u30f3\u30c1\u30e3\u30a4\u30ba\u7d4c\u55b6\u306a\u3069\u300130\u5e74\u4ee5\u4e0a\u306e\u7d4c\u9a13\u3092\u6301\u3064\u773c\u79d1\u5206\u91ce\u306e\u30d9\u30c6\u30e9\u30f3\u7d4c\u55b6\u8005<\/em><\/h3><h3 class=\"prntac\" style=\"text-align: center;\"><em>\u30a2\u30eb\u30b3\u30f3\u306e\u5143\u526f\u793e\u9577\u517c\u7db2\u819c\u90e8\u9580\u30b0\u30ed\u30fc\u30d0\u30eb\u30d8\u30c3\u30c9\u3067\u3042\u308a\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u773c\u79d1\u4e8b\u696d\u306e\u69cb\u7bc9\u3068\u62e1\u5927\u306b\u304a\u3044\u3066\u8c4a\u5bcc\u306a\u7d4c\u9a13\u3092\u6301\u3064\u3002<\/em><\/h3><h3 class=\"prntac\" style=\"text-align: center;\"><em>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u304cMCO-010\uff08MOGENRY\u2122\uff09\u306e\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u5411\u3051\u3066\u4e8b\u696d\u3092\u9032\u3081\u308b\u306b\u3042\u305f\u308a\u3001\u4eca\u56de\u306e\u4eba\u4e8b\u306f\u7d4c\u55b6\u4e0a\u306e\u30ea\u30fc\u30c0\u30fc\u30b7\u30c3\u30d7\u3092\u5f37\u5316\u3059\u308b\u3082\u306e\u3067\u3042\u308b\u3002<\/em><\/h3><p><span class=\"legendSpanClass\">\u30c0\u30e9\u30b9<\/span>,\u00a0<span class=\"legendSpanClass\">2026\u5e744\u67081\u65e5<\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u306b\u3088\u308b\u5149\u53d7\u5bb9\u4f53\u55aa\u5931\u304a\u3088\u3073\u8996\u899a\u969c\u5bb3\u306e\u60a3\u8005\u5411\u3051\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b\u306f\u672c\u65e5\u3001\u30dd\u30fc\u30eb\u30fb\u30cf\u30ec\u30f3\u6c0f\u3092\u6700\u9ad8\u57f7\u884c\u8cac\u4efb\u8005\uff08COO\uff09\u306b\u4efb\u547d\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002.<\/p><p>\u30cf\u30ec\u30f3\u6c0f\u306f\u3001\u30de\u30fc\u30b1\u30c6\u30a3\u30f3\u30b0\u3001\u55b6\u696d\u3001\u88fd\u9020\u3001\u54c1\u8cea\u7ba1\u7406\u3001\u7814\u7a76\u958b\u767a\u3001\u4e8b\u696d\u6226\u7565\u306a\u3069\u3001\u773c\u79d1\u5206\u91ce\u306b\u304a\u3051\u308b30\u5e74\u4ee5\u4e0a\u306b\u308f\u305f\u308b\u5e45\u5e83\u3044\u30ea\u30fc\u30c0\u30fc\u30b7\u30c3\u30d7\u7d4c\u9a13\u3092\u6709\u3057\u3066\u3044\u307e\u3059\u3002\u4ee5\u524d\u306f\u30a2\u30eb\u30b3\u30f3\u793e\u3067\u526f\u793e\u9577\u517c\u7db2\u819c\u90e8\u9580\u30b0\u30ed\u30fc\u30d0\u30eb\u30d8\u30c3\u30c9\u3092\u52d9\u3081\u3001\u696d\u754c\u5c48\u6307\u306e\u7db2\u819c\u95a2\u9023\u4e8b\u696d\u3092\u727d\u5f15\u3057\u307e\u3057\u305f\u3002\u307e\u305f\u3001\u7814\u7a76\u958b\u767a\u62c5\u5f53\u526f\u793e\u9577\u3068\u3057\u3066\u3001\u30a2\u30eb\u30b3\u30f3\u793e\u306e\u5404\u4e8b\u696d\u90e8\u9580\u306b\u304a\u3051\u308b\u793e\u5185\u958b\u767a\u304a\u3088\u3073\u5916\u90e8\u8cb7\u53ce\u6d3b\u52d5\u3092\u652f\u63f4\u3057\u307e\u3057\u305f\u3002\u3055\u3089\u306b\u3001\u7c73\u56fd\u7db2\u819c\u5b66\u4f1a\uff08US Retina\uff09\u306e\u7406\u4e8b\u3082\u52d9\u3081\u307e\u3057\u305f\u3002.<\/p><p>\u6700\u9ad8\u57f7\u884c\u8cac\u4efb\u8005\u3068\u3057\u3066\u3001\u30cf\u30ec\u30f3\u6c0f\u306f\u3001MCO-010\uff08MOGENRY\u2122\uff09\u306e\u898f\u5236\u5f53\u5c40\u306b\u3088\u308b\u627f\u8a8d\u3068\u767a\u58f2\u306b\u5411\u3051\u3066\u3001\u5546\u696d\u5316\u6e96\u5099\u3001\u30b5\u30d7\u30e9\u30a4\u30c1\u30a7\u30fc\u30f3\u3001\u90e8\u9580\u6a2a\u65ad\u7684\u306a\u5b9f\u884c\u306a\u3069\u3001Nanoscope\u306e\u30b0\u30ed\u30fc\u30d0\u30eb\u4e8b\u696d\u3092\u7d71\u62ec\u3057\u307e\u3059\u3002.<\/p><p>\u201c\u300c\u30dd\u30fc\u30eb\u306f\u3001\u6280\u8853\u3001\u904b\u55b6\u3001\u5546\u696d\u306e\u5c02\u9580\u77e5\u8b58\u3092\u517c\u306d\u5099\u3048\u305f\u3001\u975e\u5e38\u306b\u5c0a\u656c\u3055\u308c\u3066\u3044\u308b\u773c\u79d1\u5206\u91ce\u306e\u30ea\u30fc\u30c0\u30fc\u3067\u3059\u300d\u3068\u3001Nanoscope Therapeutics\u306e\u5171\u540c\u5275\u696d\u8005\u517c\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005\u3067\u3042\u308b\u30b9\u30e9\u30ac\u30ca\u30fb\u30d0\u30c3\u30bf\u30c1\u30e3\u30ea\u30e4\u6c0f\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u79c1\u305f\u3061\u306f\u9577\u5e74\u306b\u308f\u305f\u308a\u30dd\u30fc\u30eb\u3068\u89aa\u4ea4\u304c\u3042\u308a\u3001\u7dca\u5bc6\u306b\u4ea4\u6d41\u3057\u3066\u304d\u307e\u3057\u305f\u3002\u4eca\u56de\u306e\u5f7c\u306e\u5c31\u4efb\u306f\u3001MOGENRY\u306e\u5546\u696d\u5316\u306b\u5411\u3051\u305f\u6e96\u5099\u3092\u9032\u3081\u308b\u4e0a\u3067\u975e\u5e38\u306b\u91cd\u8981\u306a\u6642\u671f\u3067\u3059\u3002\u7db2\u819c\u3001\u88fd\u54c1\u958b\u767a\u3001\u305d\u3057\u3066\u30b0\u30ed\u30fc\u30d0\u30eb\u5c55\u958b\u8a08\u753b\u306b\u304a\u3051\u308b\u5f7c\u306e\u7d4c\u9a13\u306f\u3001\u4e16\u754c\u4e2d\u306e\u60a3\u8005\u306b\u8996\u529b\u56de\u5fa9\u7642\u6cd5\u3092\u5c4a\u3051\u308b\u4e0a\u3067\u3001\u304b\u3051\u304c\u3048\u306e\u306a\u3044\u8ca1\u7523\u3068\u306a\u308b\u3067\u3057\u3087\u3046\u3002\u300d\u201d<\/p><p>\u201c\u300c\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u767a\u5c55\u306b\u304a\u3051\u308b\u3053\u306e\u3088\u3046\u306a\u91cd\u8981\u306a\u6642\u671f\u306b\u53c2\u753b\u3067\u304d\u308b\u3053\u3068\u3092\u5927\u5909\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u300d\u3068\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306e\u6700\u9ad8\u57f7\u884c\u8cac\u4efb\u8005\u3067\u3042\u308b\u30dd\u30fc\u30eb\u30fb\u30cf\u30ec\u30f3\u6c0f\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306eMOGENRY\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u91cd\u5ea6\u306e\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u306e\u53ef\u80fd\u6027\u3092\u79d8\u3081\u305f\u3001\u6839\u672c\u7684\u306b\u5dee\u5225\u5316\u3055\u308c\u305f\u30a2\u30d7\u30ed\u30fc\u30c1\u3067\u3059\u3002MOGENRY\u306e\u627f\u8a8d\u53d6\u5f97\u306b\u5411\u3051\u3066\u30c1\u30fc\u30e0\u3068\u5354\u529b\u3057\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u4e8b\u696d\u904b\u55b6\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u5411\u3051\u305f\u6b21\u306e\u6210\u9577\u6bb5\u968e\u3078\u306e\u6e96\u5099\u3092\u652f\u63f4\u3057\u3066\u3044\u304d\u305f\u3044\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002\u300d\u201d<\/p><p><b>\u5546\u696d\u5316\u306b\u5411\u3051\u3066\u524d\u9032<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMOGENRY\u306e\u958b\u767a\u3092\u652f\u63f4\u3059\u308b\u305f\u3081\u3001\u81e8\u5e8a\u8a66\u9a13\u3001\u85ac\u4e8b\u627f\u8a8d\u3001\u304a\u3088\u3073\u91cf\u7523\u4f53\u5236\u306e\u5f37\u5316\u3092\u7740\u5b9f\u306b\u9032\u3081\u3066\u304a\u308a\u3001\u7c73\u56fd\u306b\u304a\u3051\u308b\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u306e\u9032\u6357\u72b6\u6cc1\u3082\u305d\u306e\u4e00\u3064\u3067\u3059\u3002\u307e\u305f\u3001\u7c73\u56fd\u306b\u304a\u3051\u308b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u3001\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u3001\u304a\u3088\u3073RMAT\u6307\u5b9a\u3001\u65e5\u672c\u306b\u304a\u3051\u308b\u5148\u99c6\u3051\u6307\u5b9a\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3001\u907a\u4f1d\u6027\u7db2\u819c\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u306b\u95a2\u3059\u308b5\u3064\u306eEMA\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3001\u305d\u3057\u3066\u6700\u8fd1\u3067\u306f\u30b5\u30a6\u30b8\u30a2\u30e9\u30d3\u30a2\u306b\u304a\u3051\u308b\u907a\u4f1d\u6027\u7db2\u819c\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\uff08IRD\uff09\u306b\u95a2\u3059\u308b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u306a\u3069\u3001MOGENRY\u306b\u95a2\u3059\u308b\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u85ac\u4e8b\u627f\u8a8d\u57fa\u76e4\u3082\u7740\u5b9f\u306b\u69cb\u7bc9\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u306f\u3001\u4e3b\u8981\u306a\u30b0\u30ed\u30fc\u30d0\u30eb\u5e02\u5834\u306b\u304a\u3051\u308b\u5546\u696d\u5316\u8a08\u753b\u306e\u63a8\u9032\u306b\u4f34\u3044\u3001\u540c\u793e\u304c\u56fd\u969b\u7684\u306a\u85ac\u4e8b\u627f\u8a8d\u7d4c\u8def\u3092\u62e1\u5927\u3057\u3066\u3044\u308b\u3053\u3068\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002.<\/p><p><b>MCO\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>MCO\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306a\u3069\u306e\u5149\u53d7\u5bb9\u4f53\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u3092\u76ee\u7684\u3068\u3057\u305f\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u5358\u56de\u6295\u4e0e\u306e\u785d\u5b50\u4f53\u5185\u6cbb\u7642\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002MCO\u306f\u3001\u9ad8\u5bc6\u5ea6\u306e\u53cc\u6975\u7db2\u819c\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3057\u3066\u5149\u611f\u53d7\u6027\u3092\u6301\u305f\u305b\u308b\u3053\u3068\u3067\u3001\u5149\u53d7\u5bb9\u4f53\u6b7b\u5f8c\u306b\u6b8b\u5b58\u3059\u308b\u8996\u899a\u56de\u8def\u3092\u6d3b\u7528\u3057\u307e\u3059\u3002MCO\u6cbb\u7642\u306f\u3001\u907a\u4f1d\u5b50\u691c\u67fb\u3001\u4fb5\u8972\u7684\u306a\u624b\u8853\u3001\u307e\u305f\u306f\u7e70\u308a\u8fd4\u3057\u6295\u4e0e\u3092\u5fc5\u8981\u3068\u3057\u306a\u3044\u305f\u3081\u3001\u65e2\u5b58\u306e\u7db2\u819c\u8a3a\u7642\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u5185\u3067\u5e45\u5e83\u3044\u60a3\u8005\u306b\u9069\u7528\u53ef\u80fd\u3067\u3059\u3002.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3001FDA\u3078\u306eBLA\u7533\u8acb\u304c\u9806\u6b21\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02026\u5e74\u521d\u982d\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30d5\u30a3\u30f3\u30fb\u30c7\u30a3\u30d5\u30a3\u30b7\u30eb\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001SD\u306b\u3064\u3044\u3066\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u975e\u75c7\u5019\u6027\u304a\u3088\u3073\u75c7\u5019\u6027\u306e\u687f\u4f53\u30fb\u9310\u4f53\u512a\u4f4d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3001\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3092\u5bfe\u8c61\u3068\u3059\u308bEMA\u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\uff08GA\uff09\u306b\u5bfe\u3059\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u30012026\u5e74\u521d\u982d\u306b\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002IND\u7533\u8acb\u6e96\u5099\u4e2d\u306e\u305d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u3042\u308a\u307e\u3059\u3002.<\/p><p><b>\u63a5\u89e6\uff1a<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e<br class=\"dnr\" \/>+1 (817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Veteran\u00a0ophthalmology executive with over 30 years of experience spanning R&#038;D, manufacturing, quality, commercial strategy, and franchise leadership Former Vice President and Global Head of Retina at Alcon, with deep experience building and scaling global ophthalmic franchises Appointment strengthens operational leadership as Nanoscope advances MCO-010 (MOGENRY\u2122) toward BLA submission and potential commercialization DALLAS,\u00a0April 1, 2026\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment of Paul Hallen as Chief Operating Officer. Mr. Hallen brings over 30 years of broad ophthalmic leadership experience spanning marketing, sales, manufacturing, quality, research and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10101,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10100","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T11:13:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T11:17:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\",\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"datePublished\":\"2026-04-01T11:13:37+00:00\",\"dateModified\":\"2026-04-01T11:17:26+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_Hallen_V2_Blue.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/01\\\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u773c\u79d1\u696d\u754c\u306e\u30d9\u30c6\u30e9\u30f3\u3067\u3042\u308b\u30dd\u30fc\u30eb\u30fb\u30cf\u30ec\u30f3\u6c0f\u3092\u6700\u9ad8\u57f7\u884c\u8cac\u4efb\u8005\uff08COO\uff09\u306b\u4efb\u547d\u3057\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u4e8b\u696d\u5c55\u958b\u6e96\u5099\u3092\u63a8\u9032 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-04-01T11:13:37+00:00","article_modified_time":"2026-04-01T11:17:26+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"},"wordCount":733,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","url":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u773c\u79d1\u696d\u754c\u306e\u30d9\u30c6\u30e9\u30f3\u3067\u3042\u308b\u30dd\u30fc\u30eb\u30fb\u30cf\u30ec\u30f3\u6c0f\u3092\u6700\u9ad8\u57f7\u884c\u8cac\u4efb\u8005\uff08COO\uff09\u306b\u4efb\u547d\u3057\u3001\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u4e8b\u696d\u5c55\u958b\u6e96\u5099\u3092\u63a8\u9032 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","datePublished":"2026-04-01T11:13:37+00:00","dateModified":"2026-04-01T11:17:26+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_Hallen_V2_Blue.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/01\/nanoscope-therapeutics-appoints-ophthalmology-industry-veteran-paul-hallen-as-chief-operating-officer-to-advance-global-commercial-readiness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Appoints Ophthalmology Industry Veteran Paul Hallen as Chief Operating Officer to Advance Global Commercial Readiness"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10100"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10100\/revisions"}],"predecessor-version":[{"id":10105,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10100\/revisions\/10105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10101"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}